Patient support program activations are on the rise, and enrollment dashboards appear robust. However, the persistent issue of pharmacy abandonment continues to leave specialty brand outcomes stagnant. While brand teams may perceive progress, first fill rates remain flat despite increased activation and copay engagement. The underlying challenges often do not occur at the pharmacy counter but rather upstream at critical breakpoints: missed discovery during prescribing, enrollment friction within workflows, and delays due to prior authorization or payer processes. Focusing solely on enrollment obscures the true return on investment. The specialty brands that are making significant strides are those that prioritize tracking and addressing each activation gap, emphasizing the actual number of patients who begin therapy rather than just those enrolled. This strategic shift is redefining expectations and approaches to specialty support programs.
It looks like the programs are working. Dashboards show more copay activations as e-prescribing tools gain uptake and RTBC features expand (IQVIA, 2025). Partner reports tout higher patient engagement and support program enrollment. But first fill rates show the real story. Industry data puts abandoned scripts at 98 million in 2023—a stark signal that digital enrollment and benefit visibility, while improved, cannot guarantee therapy start (Asembia, 2023).
Specialty drugs highlight the problem. Each lost first fill is potential treatment delayed, and the friction points are enormous: high out-of-pocket costs, stringent payer protocols, a thicket of onboarding requirements. Brand teams see activations improving, but therapy starts stuck in neutral. The investment is not leading to confirmed fills. Focusing on activation alone gives a false sense of progress.
Brand investment does not simply "leak" downstream. It disappears at three well-mapped breakpoints in the manufacturer's activation gap: discovery (the support never surfaces in time), enrollment friction (60% or more drop-off before completion (Asembia, 2023)), and payer or prior authorization barriers that leave the prescription stalled. Focusing on just one of these will not close the gap; they compound.
Workflow gap and activation gap are the practical terms that now matter. The workflow gap is where support fails to reach the patient or prescriber at point of decision, and the activation gap is the entire span between a written script and actual therapy start. Naming each is the first step toward tracking and closing them.
The earliest loss is timing. If copay savings or affordability offers surface after the script reaches the pharmacy, patient and prescriber are left to rescue a failed journey. More than half of patients report abandoning therapy due to high costs—price shocks at the counter drive drop-off that most support programs cannot repair after the fact (IQVIA, 2025). The answer is to surface support inside the EHR, inside the prescribing workflow, at the exact moment of therapeutic choice.
A well-crafted support program still loses a majority of potential users at the enrollment step. At this friction point, as many as 60% of interested patients drop off before full completion (Asembia, 2023). Each extra portal, form, or manual process taxes conversion. For manufacturer teams, this is the activation gap with the highest leakage per dollar spent. AI-guided enrollment and EHR-native workflow reduce this loss, but the default, when workflow is broken, is partial completion and silent abandonment.
Specialty drugs nearly all require prior authorization, making the payer/PA stage the third and often most expensive bottleneck. When ePA is not triggered before the script leaves the EHR, delays stack. Average PA takes over 15 minutes per prescription, and each hour adds risk of abandonment (Asembia, 2023). Brand investment is lost as scripts sit in limbo, not for lack of activation, but because the systems are not connected end-to-end.
All three breakpoints must be solved in a connected workflow. The activation gap is not a soft spot; it's the defining battleground for specialty brand ROI.
Legacy strategies tack on fixes: more robust patient support, digital hub enrollment, extra cost-reduction offers. Each is isolated. Support program spend, outsourced hub services, and digital portals all boost enrollment metrics. Yet all sidestep the true issue: three breakpoints and no connected system. Gaps persist because the infrastructure is not architected for through-line attribution from prescribing to therapy start.
Most vendors operate in silos—digital hubs focus on enrollment, RTBC modules on pricing visibility, ePA tools on authorization. None span all three drop-off points. A copay solution that discovers offers only at pharmacy, not at prescribing, is late. An ePA tool that triggers after pharmacy already lost the timing window. None deliver closed-loop, patient-level analytics across the activation gap.
Support arriving post-prescribing means every rescue operation is playing from behind. Each hour or day of delay magnifies drop-off. In specialty, especially, time is not neutral. Only EHR-native, real-time interventions—presenting alternatives at the moment of prescribing, triggering ePA automatically—have a shot at impacting the activation gap (IQVIA, 2025).
Manufacturers track program activations and enrollments. But without patient-level analytics tying every intervention to a therapy start, ROI remains unproven. This is now a board-level pressure: with $23 billion in annual support spending (Asembia, 2023), brand teams are being called to show which investments actually move fill rates—and which are lost in workflow and activation gaps.
The core miscalculation: equating enrollment or activation with outcome. For years, brands have counted activated cards, registered patients, or completed support calls. These metrics are easy; confirmed therapy starts are harder to find. Much of the industry celebrates the registration, but the hard loss occurs when a patient leaves the pharmacy without the therapy, often after a perfectly “successful” enrollment. The misalignment is now visible on P&L: support program spend up, confirmed first fills flat.
Advancing from enrollment to therapy start means changing the measurement boundary. This shift brings program design clarity—and puts the data burden on closed-loop analytics.
It’s not that patients fail to enroll or activate support. The problem is that manufacturers have focused intervention and measurement too early in the workflow. The true manufacturer funnel is not “enrollment” but the activation gap—the entire path from prescription written to therapy initiated. Specialty brand ROI lives and dies not at the card activation, but at each lost fill caused by disconnected workflow, enrollment friction, or payer delays.
Activation is not therapy start. Brands must now architect for confirmation, not assumption. The category’s connective language is clear: workflow gap, activation gap, confirmed start. Infrastructure must measure all the way to first fill—every copay offer, every RTBC, every ePA, every enrollment must be EHR-native, inside one connected workflow. Only then can manufacturers attribute spend to outcome and close the activation gap.
No more partial fixes. Programs that move the needle are built with six specific capabilities functioning in a single, connected workflow:
This is only possible if the workflow is EHR-native—no extra logins, no handoff to downstream portals. One connected workflow inside the EHR is the differentiator that allows real measurement of fill outcomes and closes the activation gap.
Platforms like co-pay.com sit at the intersection of these requirements. They connect co-pay discovery, RTBC, ePA, AI-guided enrollment, activation confirmation, and analytics as a single, EHR-native workflow. This is the connective layer where workflow gap and activation gap are closed, not just partially patched. Unlike legacy support vendors—who solve for enrollment but fragment discovery or prior auth—these architectures create true line-of-sight from prescription to therapy start.
Co-pay.com and similar ecosystem platforms are not just incremental tools. They build the infrastructure that binds the six manufacturer-critical capabilities, outperforming point solutions in every activation gap metric.
The true battleground is now clear: specialty brands win or lose where the activation gap gets closed, not where enrollment volume peaks. Progress depends on operational posture, not just program spend. In the coming year and a half, brands that wire their workflow to bridge all three breakpoints—surfacing support at prescribing, minimizing enrollment friction, and driving PA before pharmacy—will turn quiet investment loss into measurable therapy starts. The industry will separate those who track to the fill from those clinging to upstream metrics. Real ROI moves past wishful enrollment counts to confirmed therapy.
The therapy start gap refers to the difference between the number of specialty prescriptions written and the number of patients who actually begin therapy. While patient support program activations may be high, real-world data shows up to 27% of new prescriptions go unfilled due to payer rejections and abandonment (IQVIA, 2025). This gap is particularly pronounced in specialty drugs, where out-of-pocket costs, prior authorization, and complex workflows prevent many patients from starting prescribed therapies.
Patients may enroll in support programs but abandon before medication pickup for several reasons: cost surprises at the pharmacy, delays due to prior authorization, incomplete enrollment steps, or discovery of support resources too late in their journey. More than half of patients have reported not taking a medication because of prohibitive costs (IQVIA, 2025). Successful enrollment does not ensure therapy initiation unless these operational barriers are closed within the clinical workflow.
Enrollment refers to a patient joining a support or copay program, often indicated by card activation or consent completion. Therapy start means the patient has physically picked up and begun their medication. The two are not the same—operational data suggest that a significant share of enrolled patients never start therapy, with barriers like prior authorization, cost, or abandoned steps intervening (Asembia, 2023).
Manufacturer investment is lost at three breakpoints: (1) patients or prescribers fail to discover support options at the prescribing moment, (2) patients fall off during multi-step enrollment processes, and (3) prescriptions are rejected or delayed by prior authorization or payer rules, leading to abandonment at the pharmacy (Asembia, 2023). Each of these leak points silently erodes ROI.
Real-Time Prescription Benefit (RTBC) tools surface lower-cost drug alternatives and copay options during the prescribing encounter. As of 2025, prescribers using these tools provided patients with savings at the point of decision (IQVIA, 2025). However, their impact depends on surfacing affordability in workflow, before the script is sent. RTBC alone cannot close the therapy-start gap without connected enrollment and PA automation.
Yes. Specialty drugs, which often carry high out-of-pocket costs and require prior authorization, see higher abandonment rates. In 2023, 98 million new prescriptions were abandoned, and specialty classes are over-represented given their payer complexity and patient burden (Asembia, 2023).
Prior authorization (PA) creates substantial delay in therapy initiation. Many specialty brands report that nearly all scripts require some form of PA. Data shows that the average PA submission takes over 15 minutes per prescription, and any delay increases the risk of patient abandonment (Asembia, 2023). Automating PA and ensuring it is triggered before the pharmacy is vital to reducing this loss.
ROI for support programs should be measured at the level of confirmed therapy starts—not activations or enrollments. This requires closed-loop analytics that attribute every dollar invested to a completed first fill, using patient-level data. Currently, most commercial analytics only report on enrollment or activation, missing the real therapy initiation rates (Asembia, 2023).
An end-to-end workflow covers co-pay discovery at prescribing, real-time benefit check inside the EHR, automatic ePA before the pharmacy, in-workflow AI-guided enrollment, activation confirmation, and patient-level analytics extending through first fill. This connected system ensures support is surfaced in real time, patients encounter minimal friction, and the brand can track true ROI per script.
Platforms in this category centralize all necessary steps—co-pay discovery, RTBC, ePA, enrollment, activation confirmation, and analytics—inside the EHR as one workflow. Unlike traditional support vendors who operate in silos or downstream, these platforms close all three major breakpoints in the therapy start gap and provide brand teams with visibility from prescription to fill.